• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Kura Oncology Appoints Brian Powl as Chief Commercial Officer

    8/14/23 7:30:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KURA alert in real time by email

    SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) --  Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Brian Powl as Chief Commercial Officer. Mr. Powl joins Kura with more than 20 years of experience in building commercial brands in hematology and oncology, with a focus on developing and executing patient-focused strategies across sales, marketing and market access for global biotech and pharmaceutical products.

    "Brian is an accomplished leader with a strong track record in building successful commercial organizations and driving global commercial product launches," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "Based on the strength of our clinical data and the continued pace of enrollment in our ongoing KOMET-001 registration-enabling trial, we believe our menin inhibitor ziftomenib can become a transformational therapy in acute myeloid leukemia (AML). We look forward to Brian joining our executive leadership team and working with him to realize the significant potential value of ziftomenib as well as our farnesyl transferase inhibitor (FTI) programs."

    Mr. Powl has more than two decades of experience in the pharmaceutical and biotechnology industry, including extensive global experience in hematologic malignancies. Most recently, he served as Chief Commercial Officer for Fate Therapeutics, where he led the commercialization efforts for the company's oncology and immunology portfolio. Previously, Mr. Powl was Senior Vice President, Commercial Development & Marketing at MEI Pharma, Inc., where he led the commercialization efforts of a late-stage small molecule program in B-cell malignancies. Earlier in his career, Mr. Powl held positions of increasing responsibility at Celgene Corporation including Vice President, Global Commercial CAR T lead, where he led the commercialization efforts of ABECMA® and BREYANZI®, led ex-U.S. commercial operations, and served as the Global Marketing lead for Celgene's flagship multiple myeloma franchise during the life cycle expansion of REVLIMID® and POMALYST® into new markets and indications while strengthening the pipeline of products in myeloma. Prior to Celgene, Mr. Powl held sales and marketing positions at Novartis Oncology and Centocor, Inc. Mr. Powl holds a BS in Biochemistry from the University of California, San Diego and an MBA in Healthcare Management/Marketing from the Wharton School at the University of Pennsylvania.

    "I'm excited to join the exceptional team at Kura at this pivotal time for the company as we build a commercial organization to realize the potential of ziftomenib for patients with AML," said Mr. Powl. "With significant milestones on the horizon for the Company's menin inhibitor and FTI programs, I look forward to leading the commercial efforts, in an effort to advance Kura's mission and deliver novel therapeutics in areas of unmet patient need."

    About Kura Oncology

    Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Kura is currently enrolling patients in a Phase 2 registration-directed trial of ziftomenib in NPM1-mutant relapsed or refractory AML (KOMET-001). The Company is also conducting a series of studies to evaluate ziftomenib in combination with current standards of care, beginning with venetoclax/azacitidine and standard induction cytarabine/daunorubicin chemotherapy in NPM1-mutant and KMT2A-rearranged newly diagnosed and relapsed/refractory AML (KOMET-007). Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent HNSCC (KURRENT-HN). Kura is also preparing to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with other targeted therapies, beginning with ccRCC (FIT-001). For additional information, please visit Kura's website at www.kuraoncology.com and follow us on Twitter and LinkedIn.

    Forward-Looking Statements

    This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of ziftomenib, potential benefits of combining ziftomenib with appropriate standards of care, and progress and expected timing of the ziftomenib program and clinical trials. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, applications and other interactions with regulatory bodies, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "promise," "potential," "expects," "plans," "anticipates," "intends," "continues," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission (SEC), including the Company's Form 10-Q for the quarter ended June 30, 2023 filed with the SEC on August 9, 2023, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contacts

    Investors:

    Pete De Spain

    Executive Vice President, Investor Relations &

    Corporate Communications

    (858) 500-8833

    [email protected]

    Media:

    Alexandra Weingarten

    Senior Manager, Corporate Communications

    (858) 500-8822

    [email protected]

     



    Primary Logo

    Get the next $KURA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KURA

    DatePrice TargetRatingAnalyst
    2/6/2025Buy → Neutral
    BTIG Research
    10/24/2024$27.00Buy
    UBS
    10/14/2024$26.00 → $19.00Buy → Hold
    Stifel
    12/22/2023$26.00Buy
    Mizuho
    8/11/2023$31.00Buy
    BofA Securities
    7/27/2023$10.50Sector Perform
    Scotiabank
    5/17/2023$31.00Buy
    BTIG Research
    1/31/2023$25.00Buy
    Stifel
    More analyst ratings

    $KURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kura Oncology downgraded by BTIG Research

      BTIG Research downgraded Kura Oncology from Buy to Neutral

      2/6/25 7:53:07 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Kura Oncology with a new price target

      UBS initiated coverage of Kura Oncology with a rating of Buy and set a new price target of $27.00

      10/24/24 6:23:30 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology downgraded by Stifel with a new price target

      Stifel downgraded Kura Oncology from Buy to Hold and set a new price target of $19.00 from $26.00 previously

      10/14/24 7:36:13 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

      – Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd – – Encore presentation planned at EHA 2025 Congress – – Kura Oncology to host virtual investor event at 7:30pm ET / 4:30pm PT on June 2nd to discuss the trial results – SAN DIEGO and TOKYO, May 22, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA, "Kura")) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today announced that an abstract highlighting the full data analyses from the KOMET-001 registration-directed trial of ziftomenib, a once-daily, oral investigational menin inhibitor, has been accepted for oral presentation at the

      5/22/25 5:30:00 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology to Participate in Three Upcoming Investor Conferences

      SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three upcoming investor conferences: A fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit held virtually at 9:00 a.m. ET / 6:00 a.m. PT on May 27, 2025; A fireside chat at the Jefferies Global Healthcare Conference in NYC at 2:35 p.m. ET / 11:35 a.m. PT on June 4, 2025; and A fireside chat at the Goldman Sachs Annual Global Healthcare Conference in Miami at 11:20 a.m. ET / 8:20 a.m. PT o

      5/20/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

      – Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th – – Updated dataset to be presented in oral presentation at EHA2025 Congress – SAN DIEGO and TOKYO, May 14, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA, "Kura")) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today announced that an abstract highlighting clinical data from the KOMET-007 combination trial of ziftomenib, a once-daily, oral investigational menin inhibitor, has been accepted for presentation at the upcoming 2025 European Hematology Association (EHA) Congress, to be held in Milan, Italy, from June 12-15, 2025. KOMET-007 is a mult

      5/14/25 10:00:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Ford Kathleen sold $9,777 worth of shares (1,558 units at $6.28), decreasing direct ownership by 7% to 21,367 units (SEC Form 4)

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      5/19/25 6:30:04 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Bair Teresa Brophy sold $9,292 worth of shares (1,559 units at $5.96), decreasing direct ownership by 1% to 107,948 units (SEC Form 4)

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      5/19/25 6:30:08 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hasnain Faheem exercised 22,682 shares at a strike of $6.32 and sold $181,456 worth of shares (22,682 units at $8.00) (SEC Form 4)

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      3/24/25 4:33:39 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Kura Oncology Inc.

      SCHEDULE 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

      5/15/25 4:59:50 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Kura Oncology Inc.

      10-Q - Kura Oncology, Inc. (0001422143) (Filer)

      5/1/25 4:15:19 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Kura Oncology, Inc. (0001422143) (Filer)

      5/1/25 4:10:11 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    Financials

    Live finance-specific insights

    See more
    • Kura Oncology Reports First Quarter 2025 Financial Results

      – NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral presentation at ASCO Annual Meeting – – $45.0 million milestone payment earned for NDA submission under collaboration agreement with Kyowa Kirin – – First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST – – $703.2 million in pro forma cash, together with anticipated collaboration agreement payments, expected to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference call today at 4:

      5/1/25 4:05:00 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology to Report First Quarter 2025 Financial Results

      SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after the close of U.S. financial markets on Thursday, May 1, 2025. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 245-3047 for domestic callers and (203) 518-9765 for international callers and entering the conference ID: KURAQ1. A live webcast and

      4/24/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

      – KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpoint for potential U.S. accelerated approval pathway in frontline intensive chemotherapy trial – – Topline MRD-negative CR results from KOMET-017-IC Phase 3 trial anticipated in 2028 – – Multiple data presentations for ziftomenib and pipeline programs expected throughout 2025 – – $727.4 million in cash, together with anticipated collaboration agreement payments, to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference

      2/26/25 4:03:00 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    Leadership Updates

    Live Leadership Updates

    See more
    • Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

      – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

      10/29/24 8:00:00 AM ET
      $AMAM
      $KURA
      $RNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

      SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles is an accomplished biopharmaceutical executive with more than 25 years of oncology drug development experience and industry leadership. "On behalf of our Board and leadership team, we are delighted to have Mike join our Board of Directors," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "His extensive experience in R&D and regulatory aff

      9/17/24 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Appoints Brian Powl as Chief Commercial Officer

      SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) --  Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Brian Powl as Chief Commercial Officer. Mr. Powl joins Kura with more than 20 years of experience in building commercial brands in hematology and oncology, with a focus on developing and executing patient-focused strategies across sales, marketing and market access for global biotech and pharmaceutical products. "Brian is an accomplished leader with a strong track record in building successful commercial organizations and driving global commercial

      8/14/23 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Kura Oncology Inc.

      SC 13G - Kura Oncology, Inc. (0001422143) (Subject)

      12/5/24 6:55:37 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kura Oncology Inc.

      SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

      11/14/24 4:31:29 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kura Oncology Inc.

      SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

      11/14/24 4:32:22 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care